Hyperlipidemia is one of the most prevalent metabolic disorders worldwide. It is a significant risk factor for a range of cardiovascular diseases, including acute pancreatitis, fatty liver disease, atherosclerosis, and coronary heart disease. In clinical practice, the management of hyperlipidemia is hindered by numerous challenges. One of the critical issues is that traditional lipid-lowering drugs often require long-term or even lifelong administration, potentially inducing a range of adverse effects that compromise patient compliance and therapeutic efficacy. Therefore, there is an urgent need to develop safer and more effective strategies for the prevention and adjunctive treatment of hyperlipidemia with the aim of reducing the risk of disease and over-reliance on medication. Recent studies have revealed a close relationship between hyperlipidemia and related metabolic disorders involving gut microbiota dysbiosis, and the administration of probiotics has been shown to improve lipid metabolism homeostasis. This review summarizes the molecular mechanisms of probiotics in hyperlipidemia treatment and the latest advances in probiotic research on lipid metabolism, enumerates the experimental and clinical applications of probiotic-based therapies, introduces methods for screening and identifying probiotics with lipid-lowering functions, and, for the first time, summarizes the roles of emerging technologies such as functional genomics and in vivo zebrafish-on-a-chip models in studying the lipid-lowering efficacy of probiotics, providing insights for researchers. By facilitating a deeper understanding of the mechanisms whereby probiotics reduce blood lipid levels and furthering the development of multifaceted screening methods, we hope that we can achieve high-throughput and efficient screening of probiotics with lipid-lowering functions, thereby promoting the sustainable, high-quality, and rapid development of the probiotics industry.
Sleep disorders represent a growing global health concern with significant socio-economic impacts. GABA, a natural bioactive compound abundant in various fermented foods, especially probiotic-fermented foods, has garnered increasing attention for its potential to improve sleep quality. This review systematically elucidates the multi-pathway mechanisms by which GABA regulates sleep, focusing on (1) indirect modulation of central sleep–wake circuits via the gut–brain axis through vagal nerve, neuroendocrine, and immune pathways; (2) potential entry into the brain by leveraging the dynamic permeability of the blood–brain barrier (BBB) and transporter-mediated active transport; and (3) metabolic conversion into active substances like γ-hydroxybutyrate (GHB), which synergistically optimizes sleep architecture via multiple receptor systems and energy metabolism. Furthermore, we summarize the sleep-promoting effects of GABA-enriched foods observed in animal and clinical studies and discuss emerging applications, including high-GABA-yielding probiotics and personalized nutrition strategies for sleep intervention. This review provides a theoretical basis and innovative directions for the development of GABA-based functional foods and sleep health management.
Limosilactobacillus fermentum SHY0006 was isolated from Miao sour soup, a traditional fermented food from Guizhou, China, and systematically evaluated for its safety, metabolic functionality, and stress adaptability using phenotypic assays combined with whole-genome sequencing. SHY0006 exhibited no hemolytic activity and harbored no detectable virulence-associated or acquired antibiotic resistance genes, supporting its safety profile. Functionally, SHY0006 improved lipid metabolism and insulin resistance in both cell and animal models. In hyperlipidemic mice, hepatic triglyceride accumulation was markedly reduced, accompanied by favorable modulation of serum lipid parameters, including LDL-C, HDL-C, and free fatty acids. In diabetic mice, the strain improved insulin tolerance test (ITT) performance, indicating enhanced systemic insulin sensitivity. Whole-genome analysis revealed complete biosynthetic pathways for riboflavin and folate, along with extensive carbohydrate utilization capacity, highlighting its metabolic versatility. In addition, SHY0006 exhibited strong tolerance to environmental stress, supporting its potential viability in food matrices and gastrointestinal conditions. Collectively, these findings suggest that SHY0006 is a safe and metabolically versatile probiotic candidate with potential applications in functional foods targeting metabolic health.
Helicobacter pylori (H. pylori) infection is a major global gastrointestinal health concern, and increasing antibiotic resistance has prompted interest in complementary probiotic strategies. In this study, Lactiplantibacillus plantarum SHY0008 isolated from Miao sour soup was evaluated using integrated in vitro, AGS cell, zebrafish, murine, and genomic approaches. SHY0008 showed favorable gastrointestinal tolerance, with an acid survival rate of 39.61 ± 1.87% after 4 h under simulated gastric conditions and a relative viable recovery of 64.20 ± 6.48% after 4 h of exposure to 0.3% oxgall. SHY0008 also produced inhibition zones of 17.56 ± 0.58 mm and 17.21 ± 0.29 mm for viable and heat-treated/sonicated bacterial preparations, respectively, and reduced the H. pylori urease-associated phenol-red response by 54.23 ± 3.98%. In AGS cells, SHY0008 showed an adhesion rate of 17.53 ± 1.01% and reduced the urease-associated H. pylori adhesion signal by 48.27 ± 2.52%. In a prophylactic zebrafish model, SHY0008 pretreatment was associated with reduced intestinal H. pylori-associated fluorescence and histopathological injury following subsequent exposure. In mice, SHY0008 reduced gastric H. pylori-associated antigen and urease signals, lowered serum CXCL1/KC, and improved gastric histopathology. Whole-genome analysis identified plantaricin-associated genes, while preliminary genome-based safety screening detected no known acquired antimicrobial resistance genes or virulence-associated determinants. Collectively, these findings support SHY0008 as a promising food-derived probiotic candidate with complementary anti-H. pylori and gastroprotective activities.